Tilray (TLRY) specialises in the research, production and distribution of cannabis products. Based in Nanaimo, British Columbia (Canada), Tilray is a globally prominent figure in the medicinal marijuana industry. With regional headquarters in seven countries, the company serves tens of thousands of patients, physicians, pharmacies, researchers and governments on five continents.[1] Tilray's core business is focussed upon the medical sector and is the first good manufacturing practice (GMP) certified producer of medicinal cannabis flowers and extracts.[1]
Shares of TLRY are listed for public trade on the NASDAQ exchange. As of March 2021, TLRY held a market capitalisation of US$4.4 billion.[2] From March 2020 to March 2021, TLRY proved exceptionally volatile, posting a massive range of US$3.25-US$67.00.[2]
| Retrieved 21 Mar 2021 https://www.tilray.com/ | |
| Retrieved 21 Mar 2021 https://www.cnbc.com/quotes/TLRY |
When executing customers' trades, FXCM can be compensated in several ways, which include, but are not limited to: spreads, charging commissions at the open and close of a trade, and adding a mark-up to rollover, etc. Commission-based pricing is applicable to Active Trader account types.
Third Party Links: Links to third-party sites are provided for your convenience and for informational purposes only. FXCM bears no liability for the accuracy, content, or any other matter related to the external site or for that of subsequent links, and accepts no liability whatsoever for any loss or damage arising from the use of this or any other content. Such sites are not within our control and may not follow the same privacy, security, or accessibility standards as ours. Please read the linked websites' terms and conditions.
Any opinions, news, research, analyses, prices, other information, or links to third-party sites contained on this website are provided on an "as-is" basis, as general market commentary and do not constitute investment advice. The market commentary has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is therefore not subject to any prohibition on dealing ahead of dissemination. Although this commentary is not produced by an independent source, FXCM takes all sufficient steps to eliminate or prevent any conflicts of interests arising out of the production and dissemination of this communication. The employees of FXCM commit to acting in the clients' best interests and represent their views without misleading, deceiving, or otherwise impairing the clients' ability to make informed investment decisions. For more information about the FXCM's internal organizational and administrative arrangements for the prevention of conflicts, please refer to the Firms' Managing Conflicts Policy. Please ensure that you read and understand our Full Disclaimer and Liability provision concerning the foregoing Information, which can be accessed here.